Syncom Formulations Holds 38th AGM on Sep 30, 2026; Dividend Declared
Syncom Formulations held its 38th AGM on Sep 30, 2026. The company declared a 10% dividend (₹0.10 per share) for FY26. Key appointments including Rahul Vijay Bankda as MD and Rinki Ankit Bankda as Whole-Time Director were confirmed. Remuneration for CFO Ankur Vijay Bankda was also approved.
The declaration of a dividend and confirmation of key management positions are material events for shareholders and stakeholders, influencing the company's governance and financial distribution.
The announcement details the successful conduct of the AGM, the declaration of a dividend, and confirmation of key management appointments, all of which are generally positive corporate actions.
Syncom Formulations (India) Limited held its 38th Annual General Meeting (AGM) on Wednesday, September 30, 2026, from 2:00 P.M. to 2:42 P.M. IST, conducted through Video Conferencing (VC) / Other Audio Video Means (OAVM).
During the meeting, shareholders approved the adoption of the Standalone and Consolidated Audited Financial Statements for the Financial Year ended March 31, 2026. A dividend of 10%, amounting to ₹0.10 per equity share of face value ₹1, was declared for the same financial year.
Key personnel appointments and re-appointments were also confirmed. Mr. Ankit Kedarmal Bankda was re-appointed as a Director retiring by rotation. Mr. Rahul Vijay Bankda's appointment as Director and Managing Director, along with his remuneration, was confirmed. Similarly, Mrs. Rinki Ankit Bankda's appointment as Director and Whole-Time Director, with remuneration, was approved. Mrs. Ruchi Jindal was re-appointed as a Woman Independent Director.
Furthermore, the remuneration of the Cost Auditor for FY 2026-27 was ratified, and the increase in remuneration for Mr. Ankur Vijay Bankda, Chief Financial Officer, was approved.
The results of the e-voting, conducted both remotely and during the AGM, will be intimated separately upon receipt of the Scrutinizer's Report within two working days.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.